[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:malignant-neoplasm-of-cardio-esophageal-junction-of-stomach:erbb2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Malignant neoplasm of cardio-esophageal junction of stomach","ERBB2 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",[12],"Phase 2","RECRUITING","2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.744064Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers",[20],"Phase 1","2026-08-26T02:18:31.944757Z","2026-05-05T02:35:31.700916Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT06109467","Neratinib In Combination With Chemotherapy\u002FTrastuzumab\u002FPembrolizumab In HER2 Gastroesophageal Cancer",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:11:04.414058Z","2026-05-05T02:43:28.964978Z"]